Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682962 | 1.00 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL10661597 | 1.00 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL7948406 | 1.00 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL8789697 | 1.00 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL375988 | 1.00 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL313768 | 1.00 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL6266811 | 0.99 | PNP (0.47) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL8790893 | 0.85 | KDM4E (0.44) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL3901295 | 0.85 | KDM4E (0.44) | PNPMAPTCYP3A4KDM4EGMNN | |
| SCHEMBL10663518 | 0.80 | HIF1A (0.46) | MAPTCYP3A4KDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3244922-A1 | METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS | Agrawal, Babita (CA) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016112459-A1 | METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS | AGRAWAL BABITA (CA) | 2016-07-21 | — | — | WO | disclosed |
| EP-2341924-A2 | METHODS OF TREATING HEPATITIS C VIRUS INFECTION | The J. David Gladstone Institutes (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010081095-A2 | METHODS AND COMPOSITIONS FOR INHIBITING HEPATITIS C VIRUS REPLICATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010039195-A2 | SCREENING FOR INHIBITORS OF HCV AMPHIPATHIC HELIX (AH) FUNCTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010039801-A2 | METHODS OF TREATING HEPATITIS C VIRUS INFECTION | THE J. DAVID GLADSTONE INSTITUTES (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-1789074-A4 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090186358-A1 | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof | WYETH (US) | 2009-07-23 | — | — | US | disclosed |
| EP-1858326-A4 | METHODS OF TREATING GASTROINTESTINAL INFLAMMATION | UNIV CALIFORNIA (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1858326-A1 | METHODS OF TREATING GASTROINTESTINAL INFLAMMATION | The Regents of the University of California (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1789074-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006091591-A1 | METHODS OF TREATING GASTROINTESTINAL INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006020580-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1017394-B1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER REC TECH LTD (GB) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005110455-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005067963-A1 | USE OF POLYETHYLENE GLYCOL-MODIFIED INTERFERON-ALPHA IN THERAPEUTIC DOSING REGIMENS | INTERMUNE, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005062949-A2 | METHOD FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-6303618-B1 | ADMINISTERING PURINE COMPOUND WHICH INHIBITS CYCLIC DEPENDENT KINASE ACTIVITY FOR THERAPY OF TUMOR OR OTHER CELL PROLIFERATION DISORDER | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| WO-1999002162-A9 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RES CAMPAIGN TECH (GB) | 1999-07-29 | — | — | WO | disclosed |